"The world's largest molecular library
0.000 million compounds
0.000 billion conformers"

  • Smarter

    Carmolex develops molecules catered to the biochemistry of the target through smart technology.
  • Faster

    Carmolex virtual screening services operate fast to sort through billions of configurations of molecules.
  • Better

    Bringing together our knowledge of biochemistry with our advanced computational capability yields better results.
  • 1
  • 2
  • 3

Redefining Drug Discovery

To develop and market drugs successfully, pharmaceutical companies require a library of compounds that is diverse, replenishable, and of optimal quality. In today’s pharmaceutical industry, however, drug developers’ libraries are biased toward historical targets that provide the exact opposite—libraries that have been depleted, are unsustainable, and yield low hit rates against protein targets. Consequently, this multi-billion dollar industry faces unprecedented rates of patent expirations, and this in turn creates a remarkably high market demand for effective solutions.

To help pharmaceutical companies develop top-tier compound libraries, CARMOLEX Inc. has developed disruptive, enabling technologies that facilitate the large-scale design, synthesis and validation of small molecule protein antagonists. In doing so, we offer our clients the largest, most robust chemical libraries worldwide—a critical and necessary step in replenishing their drug pipelines, patent portfolios, and shareholder value.

Read More

 

---------Redefining Drug Discovery-------------

 

CARMOLEX Inc. has developed disruptive, enabling technologies that facilitate the large-scale design, synthesis and validation of small molecule protein antagonists.  In doing so, we offer our clients the largest, most robust chemical libraries worldwide—a critical and necessary step in replenishing their drug pipelines, growing their patent portfolios, and building shareholder value.